These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8364920)

  • 1. Bovine serum albumin-doxorubicin conjugate overcomes multidrug resistance in a rat hepatoma.
    Ohkawa K; Hatano T; Yamada K; Joh K; Takada K; Tsukada Y; Matsuda M
    Cancer Res; 1993 Sep; 53(18):4238-42. PubMed ID: 8364920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapeutic efficacy of the protein-doxorubicin conjugates on multidrug resistant rat hepatoma cell line in vitro.
    Ohkawa K; Hatano T; Tsukada Y; Matsuda M
    Br J Cancer; 1993 Feb; 67(2):274-8. PubMed ID: 8431358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug conjugate of doxorubicin with glutathione is a potent reverser of multidrug resistance in rat hepatoma cells.
    Asakura T; Takahashi N; Takada K; Inoue T; Ohkawa K
    Anticancer Drugs; 1997 Feb; 8(2):199-203. PubMed ID: 9073316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Intracellular distribution of bovine serum albumin-conjugated doxorubicin and multidrug resistance].
    Takahashi N; Asakura T; Ohkawa K; Fukuda K; Aoki T
    Gan To Kagaku Ryoho; 1997 Jan; 24(1):87-92. PubMed ID: 9020950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic analysis of protein-conjugated doxorubicin (DXR) and its degraded adducts in DXR-sensitive and -resistant rat hepatoma cells.
    Takahashi N; Asakura T; Ohkawa K
    Anticancer Drugs; 1996 Aug; 7(6):687-96. PubMed ID: 8913438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutathione-doxorubicin conjugate expresses potent cytotoxicity by suppression of glutathione S-transferase activity: comparison between doxorubicin-sensitive and -resistant rat hepatoma cells.
    Asakura T; Ohkawa K; Takahashi N; Takada K; Inoue T; Yokoyama S
    Br J Cancer; 1997; 76(10):1333-7. PubMed ID: 9374380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caspase-3 activation during apoptosis caused by glutathione-doxorubicin conjugate.
    Asakura T; Sawai T; Hashidume Y; Ohkawa Y; Yokoyama S; Ohkawa K
    Br J Cancer; 1999 May; 80(5-6):711-5. PubMed ID: 10360648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic effect of the protein-doxorubicin conjugates on the multidrug-resistant human myelogenous leukemia cell line, K562, in vitro.
    Hatano T; Ohkawa K; Matsuda M
    Tumour Biol; 1993; 14(5):288-94. PubMed ID: 8235308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quinine circumvents the doxorubicin resistance of a multidrug resistant human leukemic cell-line, K562/DXR.
    Solary E; Velay I; Chauffert B; Caillot D; Bidan JM; Dumas M; Casasnovas O; Guy H
    Nouv Rev Fr Hematol (1978); 1990; 32(5):361-3. PubMed ID: 2099412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of GST-P by treatment with glutathione-doxorubicin conjugate induces potent apoptosis in rat hepatoma cells.
    Asakura T; Hashizume Y; Tashiro K; Searashi Y; Ohkawa K; Nishihira J; Sakai M; Shibasaki T
    Int J Cancer; 2001 Oct; 94(2):171-7. PubMed ID: 11668494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.
    Hyafil F; Vergely C; Du Vignaud P; Grand-Perret T
    Cancer Res; 1993 Oct; 53(19):4595-602. PubMed ID: 8402633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of bispecific monoclonal antibody recognizing both hepatoma-specific membrane glycoprotein and anthracycline drugs on the metastatic growth of hepatoma AH66.
    Tsukada Y; Ohkawa K; Hibi N; Tsuzuki K; Oguma K; Satoh H
    Cancer Biochem Biophys; 1989 May; 10(3):247-56. PubMed ID: 2789098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristic changes in protein-kinase-C activity and isoforms in ah66 cells during the acquisition of multidrug-resistant phenotype.
    Ohkawa K; Hatano T; Isonishi S; Takada K; Joh K; Matsuda M
    Oncol Rep; 1994 May; 1(3):551-5. PubMed ID: 21607402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced cardiotoxicity and nephrotoxicity with preservation of antitumor activity of doxorubicin entrapped in stable liposomes in the LOU/M Wsl rat.
    van Hoesel QG; Steerenberg PA; Crommelin DJ; van Dijk A; van Oort W; Klein S; Douze JM; de Wildt DJ; Hillen FC
    Cancer Res; 1984 Sep; 44(9):3698-705. PubMed ID: 6744286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro reversal MDR of human carcinoma cell line by an antisense oligodeoxynucleotide-doxorubicin conjugate.
    Ren Y; Zhan X; Wei D; Liu J
    Biomed Pharmacother; 2004 Nov; 58(9):520-6. PubMed ID: 15511610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro evaluation of a Folate-bovine serum albumin-doxorubicin conjugate.
    Qu X; Yang C; Zhang J; Ding N; Lu Y; Huang L; Xiang G
    J Drug Target; 2010 Jun; 18(5):351-61. PubMed ID: 20001219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental treatment of malignant gliomas with human monoclonal antibody-drug conjugates.
    Takahashi H; Adachi K; Yamaguchi F; Teramoto A
    Anticancer Res; 1999; 19(5B):4151-5. PubMed ID: 10628367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment and serial quantification of intrahepatic xenografts of human hepatocellular carcinoma in severe combined immunodeficiency mice, and development of therapeutic strategies to overcome multidrug resistance.
    Leveille-Webster CR; Arias IA
    Clin Cancer Res; 1996 Apr; 2(4):695-706. PubMed ID: 9816220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming multidrug resistance in human carcinoma cells by an antisense oligodeoxynucleotide--doxorubicin conjugate in vitro and in vivo.
    Ren Y; Wang Y; Zhang Y; Wei D
    Mol Pharm; 2008; 5(4):579-87. PubMed ID: 18461970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells.
    Kobayashi T; Ishida T; Okada Y; Ise S; Harashima H; Kiwada H
    Int J Pharm; 2007 Feb; 329(1-2):94-102. PubMed ID: 16997518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.